Control
Fenretinide (LAU-7b) is an oral small molecule host-directed therapy that targets host cell membrane lipid pathways to exert antiviral and inflammation-resolving effects.
May 30 2024 |
et al., NCT04417257 | RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease |
| 44% higher mortality (p=0.34). RCT 125 hospitalized COVID-19 patients showing no significant benefits with fenretinide (LAU-7b). | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.